Journal of Clinical Oncology (JCO) Podcast

Estrogen plus progestin and estrogen alone have different effects on mammographic density and breast cancer.

This is a commentary on a recent study comparing two risk calculators for use in the setting of prostate cancer screening.

This podcast describes the analysis of the IPASS study population by EGFR mutation and EGFR FISH biomarker status, and also discusses the results and controversial analysis of overall survival from this trial.

The use of arsenic trioxide as a single agent can produce long lasting remissions and a significant cure rate in patients with acute promyelocytic leukemia.

In this podcast, results of randomized phase III clinical trial evaluating the effects of a patient specific idiotype tumor vaccine in patients with follicular lymphoma are summarized. The results demonstrate that idiotype vaccination may improve disease free survival in patients with follicular lymphoma who achieve a remission following chemotherapy.

The addition of oxaliplatin to fluorouracil-based neoadjvuant chemoradiation for locally advanced rectal cancer significantly increases toxicity but does not improve the pathologic complete response rate.

The term targeted therapy is often used in cancer drug development. This podcast will discuss the study of a mEK inhibitor where the investigators actually looked at the impact on the target as well as whether the drug worked or did not work.

Commentary on a new small molecule inhibitor of angiogenesis in combination with chemotherapy for metastatic breast cancer.

This SEER based study demonstrated that the advanced radiation therapy technique of three-dimensional conformal radiation therapy improved survival compared to the previously used method.

This podcast will discuss the basic background of myelodysplastic syndromes and the clinical implications of TP53 mutations predicting outcomes in del(5q) MDS.

This podcast describes the long term outcomes of patients treated with chemotherapy first, followed by either cystectomy or radiation therapy. It provides important information to practicing physicians who treat this disease in helping make decisions about the utility and effectiveness, as well as safety, of using chemotherapy for muscle invasive bladder cancer.

In this week's podcast, Dr. Jaine discusses the recent manuscript by Paik and colleagues evaluating BRAF mutations in patients with advanced lung cancer. The potential impact of BRAF mutations and outcomes with current therapies for lung cancer are discussed.

In this podcast, Dr. Neal J. Meropol provides his perspective on two large randomized studies of vatalanib in patients with metastatic colorectal cancer.

By Mary Daly. Stage at diagnosis of breast cancer among women with BRCA1/2 mutations was available for women enrolled in a multi-modality screening protocol including breast MRI, and for women who were screened with routine mammography. There was a significant increase in early stage at diagnosis for women in the MRI protocol compared to those in the mammography alone group.

By David Ryan. This JCO Podcast provides observations and commentary on the JCO article, "Clinical Significance of Circulating Tumor Cells Including Cancer Stem-like Cells in Peripheral Blood for Recurrence and Prognosis in Colorectal Cancer Patients with Dukes stage B and C" by authors Hisae Iinuma, et al.

By Reed Drews. This JCO Podcast provides observations and commentary on the JCO article, "Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis" by authors Animesh Pardanani, et al.

By Lisa Carey. The randomized Phase III trial, Ribbon-1, was designed to examine whether the benefit of bevacizumab added to chemotherapy in metastatic breast cancer was specific to the taxanes or if the benefit could accrue regardless of the chemotherapy backbone. PFS was improved with the addition of bevacizumab to several cytotoxics, including capecitabine, taxanes, and anthracyclines. OS was n...

By David Avigan. This podcast describes a phase III randomized study comparing the efficacy and toxicity of Denosumab with Zolendronic Acid for the prevention of skeletal complications in patients with malignancy.